Takeda Pharmaceutical Limited (TKPHF) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Takeda Pharmaceutical Li...

    OTC: TKPHF · Real-Time Price · USD
    30.40
    0.00 (0.00%)
    At close: Sep 08, 2025, 10:39 AM
    30.40
    0.00%
    After-hours: Sep 09, 2025, 08:00 PM EDT

    Takeda Pharmaceutical Income Statement

    Financials in JPY. Fiscal year is April - March.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Mar 31, 2025 Mar 31, 2024 Mar 31, 2023 Mar 31, 2022
    Revenue
    		 4,581.6B 4,263.8B 4,027.5B 3,569B
    Cost of Revenue
    		 1,580.2B 1,431.5B 1,244.1B 1,106.8B
    Gross Profit
    		 3,001.3B 2,832.3B 2,783.4B 2,462.2B
    Operating Income
    		 342.59B 214.07B 490.5B 460.84B
    Interest Income
    		 19.64B 11.29B 62.91B 23.7B
    Pretax Income
    		 175.08B 52.79B 375.09B 302.57B
    Net Income
    		 107.93B 144.07B 317.02B 230.06B
    Selling & General & Admin
    		 1,104.8B 1,053.8B 997.31B 886.36B
    Research & Development
    		 730.23B 729.92B 633.33B 526.09B
    Other Expenses
    		 823.75B 834.44B -9.47B -20.72B
    Operating Expenses
    		 2,658.7B 2,618.2B 2,292.9B 2,001.3B
    Interest Expense
    		 137.31B 119.53B 169.7B 166.61B
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 4,239B 4,049.7B 3,537B 3,108.2B
    Income Tax Expense
    		 66.94B -91.41B 58.05B 72.41B
    Shares Outstanding (Basic)
    		 1.58B 1.56B 1.55B 1.56B
    Shares Outstanding (Diluted)
    		 1.61B 1.58B 1.57B 1.58B
    EPS (Basic)
    		 68.36 92.09 204.29 147.14
    EPS (Diluted)
    		 67.23 91.16 201.94 145.87
    EBITDA
    		 1,073.8B 900.33B 1,156.5B 1,183.2B
    EBIT
    		 312.39B 172.33B 492.06B 425B
    Depreciation & Amortization
    		 761.4B 728B 664.4B 583.15B

    Add to Watchlist